期刊文献+

HPLC法测定替吉奥片中3种成分的含量 被引量:10

Determination of Three Components in Tegafur,Gimeracil and Oteracil Potassium Tablets by HPLC
下载PDF
导出
摘要 建立高效液相色谱法测定替吉奥片中奥替拉西钾、吉美拉西以及替加氟的含量。采用KromasilC18色谱柱;流动相:磷酸二氢钾缓冲溶液(取磷酸二氢钾1.36g,加水800mL与三乙胺10mL,用磷酸调pH至4.5)-甲醇(85∶15),流速:1.0mL·min-1,检测波长:266nm,进样量:10μL,柱温:室温。奥替拉西钾、吉美拉西和替加氟分别在0.17~2.82μg(r=0.9993),0.06~0.81μg(r=0.9996),0.16~2.88μg(r=0.9998)范围内线性良好。平均回收率分别为99.8%(RSD=0.31%),99.7%(RSD=0.73%),99.9%(RSD=0.38%)。该方法简单、灵敏、准确、专属性强,可用于替吉奥片的质量控制。 A HPLC method for the quantitative analysis of three contents in Tegafur, Gimeracil and Oteracil Potassium Tablets was established. The column was Kromasil C18 column. The mobile phase was potassium dihydrogen phosphate buffer solution (dissolve 1.36g potassium dihydrogen phosphate in 800mL of water and 10mL of triethylamine, adjust to pH 4.5 by H3PO4) -methanol (85 : 15). The detection wavelength was 266nm. The column temperature was kept at the room temperature. The flowrate was 1.0mL · min^-1. The calibration curves of oteracil potassium, gimeracil, and tegafur were linear in the range of 0.17 0 2. 82μg, 0. 06 - 0. 81μg, 0.16 - 2. 88μg, respectively. The average recovery was 99.8%, 99.7%, 99.9%, and RSD was 0. 31%, 0.73%, 0.38% (n=5), respectively. The method is simple, sensitive and accurate. It can be used for determination of Tegafur, Gimeracil and Oteracil Potassium Tablets.
作者 孙莉
出处 《中国药事》 CAS 2008年第11期984-986,共3页 Chinese Pharmaceutical Affairs
关键词 高效液相色谱法 替吉奥片 奥替拉西钾 吉美拉西 替加氟 HPLC Tegafur Gimeracil and Oteracil Potassium Tablets oteracil potassium gimeracil tegafur
  • 相关文献

参考文献7

  • 1Sato A, Ito T, Tomita T, et al. Chemotherapy of gastric cancer-a review of clinical trials in Japan [J]. Gan To Kagaku Ryoho, 2002, 29 (9): 1522.
  • 2Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents [J]. Curt Pharm Biotechnol, 2000, 1 (2): 137.
  • 3Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity of fluoropyrimidines by metabolic and target enzyme activities in gastric cancer [J]. Gastric Cancer, 2003, 6 (Suppl 1): 71.
  • 4Yoshisue K, Hironaga K, Yamaguchi S, et al. Reduction of 5- fluorouracil gastroiontestinal toxicity resulting from the prtection of thymidylate synthase in gastrointestinal tissue by repeated simultaneous administration of potassium oxonate in rats [J]. Cancer ChemotherPharmacol, 2000, 46 (1): 51.
  • 5Yoshisue K, Masuda H, Matsushima E, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent(drug combination of tegafur, 5- chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats[J]. Drug Metab Dispos, 2000,28 (10) : 1162.
  • 6戚苏明,刘江华,曹燕锋,蔡伟,顾志兰.替吉奥胶囊处方优选[J].中国药业,2006,15(11):44-45. 被引量:3
  • 7张晗.治疗胃癌的复方新药S-1的研究进展[J].国外医学(药学分册),2005,32(5):304-307. 被引量:8

二级参考文献20

  • 1Sato A, Ito T, Tomita T, et al. Chemotherapy of gastric cancer-a review of clinical trials in Japan[J]. Gan To Kagaku Ryoho ,2002,29(9): 1522 - 1531.
  • 2Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents [J]. Curr Pharm Biotechnol, 2000, 1(2):137-164.
  • 3Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of5-fluorouracil (capecitabine, UFT, S-1): a review[J]. Oncologist, 2002, 7(4) :288 - 323.
  • 4Diaz-Canton E, Pazdur R. Preoperative combined oral UFT plus leucovorin and radiation therapy for rectal cancer[J]. Oncology(Williston Park), 1997, 11(9 Suppl 10):58-60.
  • 5Hoff PM. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential[J]. Invest New Drugs, 2000, 18(4) :331 - 342.
  • 6Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer[J]. Gastric Cancer, 2003, 6(Suppl 1) :71 - 81.
  • 7Yoshisue K, Hironaga K, Yamaguchi S, et al. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats[J]. Cancer Chemother Pharmacol, 2000, 46(1):51-56.
  • 8Yoshisue K, Masuda H, Matsushima E, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent ( drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats[J].Drug Metab Dispos, 2000, 28(10):1162- 1167.
  • 9Takechi T, Okabe H, Ikeda K, et al. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts[J]. Oncol Rep, 2005, 14(1):33- 39.
  • 10Hayashi T, Tanaka G, Irimura K, et al. Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP and Oxo[J]. J Toxicol Sci, 1996, 21(Suppl 3) :495 - 504.

共引文献9

同被引文献78

引证文献10

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部